8-K: Gyrodyne Navigates Headwinds, Targets 2027 Property Sales

Gyrodyne, LLC provided an update on its property sales, ongoing litigation, and financial performance, revealing a decrease in estimated liquidating distributions per share despite an increase in total net asset value.

Summary

• Stated goals remain to sell properties at post-entitled values and make liquidating distributions as soon as possible, despite economic headwinds in commercial and medical office markets.
• Corporate governance changes include reducing Board size to 4 members and capping the Chairman's fee at $65,000 (down from $120,000).
• Full-time employees reduced to three, including the President/CEO/CFO.
• An agreement was signed in July 2025 for the sale of 49 undeveloped acres of the Flowerfield complex for a gross closing price of $28.74 million, anticipated to close at the end of 2027, contingent on Article 78 settlement and site plan approval.
• The Cortlandt Manor property received Medical Oriented District designation and entitlements for up to 150,000 square feet of medical office and 4,000 square feet of retail use; the company is now exploring mixed-use development with a residential component due to a weakened medical office market.
• The Article 78 litigation appeal is ongoing, with a hearing date awaited from the appellate court and a decision anticipated in 2027.
• Costs in excess of operating receipts (excluding land development costs) were approximately $700,000 for the first six months of 2025, an increase of $125,000 from the first six months of 2024.
• The occupancy rate was 85% as of June 2025, a slight decrease from 86% in December 2023.
• Estimated liquidating distributions decreased to $14.83 per share as of June 2025, down from $15.98 per share (adjusted for rights offering) as of December 2023, primarily due to a timeline extension through December 31, 2027.
• Total Net Asset Value (NAV) increased by approximately $1.65 million, from $30,721,034 at year-end 2023 to $32,608,865 in June 2025, driven by $4.4 million in net proceeds from a Rights Offering, offset by the timeline extension.
• Total principal of loans outstanding was $11.0 million as of June 30, 2025, with an annual debt service of approximately $1 million ($300,000 principal).
• A $1.5 million term loan facility, bearing interest at 8.75%, is maturing in December 2025 and will likely be repaid.
• The forecasted annual burn rate is $1.5 million, excluding land development and Article 78 related litigation expenses.

Sentiment

Score: 4

Explanation: The filing presents a mixed outlook. While there's a significant property sale agreement and an increase in total NAV, the decrease in NAV per share, extended timelines for key events (litigation, property sales), increased operating costs, and challenging market conditions for medical office properties suggest a slightly negative sentiment. The company is taking proactive steps in governance and strategy, but external factors and delays weigh heavily.

Positives

• Secured an agreement for the sale of 49 undeveloped acres of the Flowerfield complex for a gross closing price of $28.74 million.
• Cortlandt Manor property received Medical Oriented District designation and entitlements for up to 150,000 square feet of medical office and 4,000 square feet of retail use.
• Implemented significant corporate governance improvements, including a reduction in Board size to 4 members and a reduction of the Chairman's fee from $120,000 to a cap of $65,000.
• Reduced full-time employees to three, demonstrating a focus on cost management.
• Total Net Asset Value (NAV) increased by approximately $1.65 million, from $30,721,034 at year-end 2023 to $32,608,865 in June 2025.
• Achieved a $120,000 increase in gross margin on rental operations (inclusive of cap ex) and a $60,000 reduction in G&A expenses in H1 2025 compared to H1 2024.
• Benefited from higher interest income of approximately $25,000 in H1 2025.
• Debt service on three term loans was largely unaffected by Federal Reserve interest rate increases prior to December 2023 due to fixed rates ranging from 3.75% to 3.85%.

Negatives

• Estimated liquidating distributions per share decreased from $15.98 (adjusted for rights offering) as of December 2023 to $14.83 as of June 2025.
• Costs in excess of operating receipts (excluding land development costs) increased by approximately $125,000 in the first six months of 2025 compared to the same period in 2024, reaching $700,000.
• The occupancy rate slightly degraded to 85% as of June 2025 from 86% at December 2023.
• The market for medical office properties has significantly weakened following the pandemic, exacerbated by economic headwinds facing hospitals.
• The resolution of the Article 78 litigation and the closing of the 49-acre Flowerfield sale are not anticipated until 2027, indicating extended timelines.
• A $1.5 million term loan facility, bearing interest at 8.75%, is maturing in December 2025 and will likely require repayment or modification.
• The forecasted annual burn rate is $1.5 million, excluding land development and Article 78 related litigation expenses.
• Real estate values discussed largely reflect values prior to current interest rates and escalating inflation, suggesting potential downward pressure on ultimate realized values.

Risks

• Economic headwinds adversely affecting the publicly traded commercial office market and continued headwinds facing hospital systems and related demand for medical office.
• Success of property sales and overall efforts contingent on securing entitlements.
• Uncertainty and potential delays in the Article 78 litigation decision, with the court's docket remaining backed up from the legacy impact of COVID-19.
• The ultimate value realized from property sales is largely dependent on the success of the post-pandemic economic recovery, inflation, the stabilization of interest rates, and the speed at which courts operate and municipalities act.
• The $1.5 million term loan facility maturing in December 2025 will likely be repaid absent any agreement with the lender to modify the facility at acceptable terms, potentially impacting liquidity.
• No assurances can be given regarding the receipt of final entitlements and subsequent sales of individual properties.

Future Outlook

Gyrodyne anticipates receiving final entitlements for its Flowerfield property in the first quarter of 2026 and expects a decision on the Article 78 proceeding in 2027, which is crucial for the planned $28.74 million sale of 49 acres by the end of 2027. The company is actively marketing its Cortlandt Manor property, exploring a shift to mixed-use development including a residential component to enhance marketability and value. Management remains open to offers for properties 'as is' or for the sale of the entire company, acknowledging that ultimate value depends on economic recovery, inflation, interest rate stabilization, and the pace of legal and municipal processes.

Management Comments

• "Despite the economic headwinds that adversely affected the publicly traded commercial office market over recent years and the continued headwinds facing hospital systems and the related demand for medical office, our stated goals remain unchanged sell the properties at post entitled values and make liquidating distributions as soon as possible."
• "We are optimistic our arguments will successfully defend our Rights and lead to a favorable ruling [on the Article 78 appeal]."
• "We anticipate the sale of the 49 acres will close at the end of 2027 for a gross closing price of $28.74 million."
• "The property [Cortlandt Manor] is now positioned for sale at post-entitled values."
• "We are reviewing alternative paths to market the property [Cortlandt Manor], including attracting potential developers interested in mixed use development which we believe is more attractive to developers in Cortlandt Manor, a pathway that we believe will result in an earlier sale and improved NAV on a risk adjusted basis."
• "We now believe that renewed strong demand for multi-family residential may provide for more favorable conditions for us to revert to partial residential use in our site plan and subdivision application, which we believe would make our Cortlandt Manor property more marketable and valuable."
• "While we still believe final entitlements and subsequent sales of individual properties will maximize distributions to shareholders, we remain open to offers for the properties as is and where is and or for sale of the Company itself."

Industry Context

The company operates within a challenging real estate market, facing significant economic headwinds in the commercial office sector and continued difficulties for hospital systems impacting demand for medical office properties. The market for medical office properties has notably weakened post-pandemic. However, there is a renewed strong demand for multi-family residential development, which the company is now considering for its Cortlandt Manor property to improve marketability.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess the company's performance against global benchmarks or industry standards. It primarily discusses general industry headwinds affecting commercial and medical office markets.

Management Changes

Corporate Governance

Legal Proceedings

• Defending subdivision rights during the petitioners' Appeal of the Article 78 proceeding.
• Awaiting notification from the appellate court for the hearing date on the Article 78 lawsuit.
• Anticipate a decision will be issued by the Court in 2027, though the pace is uncontrollable due to court backlogs.

Stakeholder Impact

• Shareholders: Face extended timelines for liquidating distributions (anticipated end of 2027) and a decrease in estimated liquidating distributions per share ($14.83 vs $15.98), though total NAV increased. Corporate governance changes aim to address shareholder feedback.
• Employees: Reduction in full-time employees to three, indicating a leaner operational structure.
• Customers (tenants): Occupancy rate slightly decreased, and the company is pressured to increase occupancy and average rate per square foot due to market degradation and inflation.
• Creditors: A $1.5 million term loan matures in December 2025, requiring repayment or modification. Other loans are fixed-rate, providing some stability.

Next Steps

• Await notification from the appellate court for the hearing date regarding the Article 78 proceeding.
• Anticipate a decision on the Article 78 lawsuit in 2027.
• Anticipate the receipt of final entitlements on Flowerfield in the first quarter of 2026.
• Actively market the Cortlandt Manor property with the goal of entering into sales agreements at post-entitled values.
• Review alternative paths to market the Cortlandt Manor property, including attracting developers interested in mixed-use development with a residential component.
• Potentially revert to partial residential use in the Cortlandt Manor site plan and subdivision application and jointly present the case to the Town with a developer.
• Repay the $1.5 million term loan facility maturing in December 2025, absent any agreement with the lender to modify the facility at acceptable terms.
• Continue to review costs with a focus on cost/benefit and associated risk management.
• Remain open to offers for the properties "as is and where is" or for the sale of the company itself.

Key Dates

Recommendation

The company is navigating significant economic headwinds in its core markets (commercial and medical office) and faces prolonged legal and entitlement processes, pushing out the timeline for asset monetization and liquidating distributions to shareholders until at least late 2027. While the agreement to sell 49 acres for $28.74 million is a positive step, its contingency on litigation resolution and site plan approval introduces uncertainty. The decrease in estimated liquidating distributions per share, despite an increase in total NAV, reflects these extended timelines and ongoing costs. Management has taken commendable steps in corporate governance and cost reduction, and is proactively exploring alternative development strategies for Cortlandt Manor. However, the long-term nature of the asset realization process, coupled with market volatility and a forecasted annual burn rate, suggests a 'hold' recommendation. Investors should monitor progress on entitlements, litigation, and the successful execution of property sales, as these will be key determinants of future value.

Keywords

real estate development, commercial property, medical office, land sales, entitlements, litigation, corporate governance, net asset value, liquidating distributions, Flowerfield, Cortlandt Manor, SEC filing, 8-K, property sales, asset management